Kosmala, Aleksander http://orcid.org/0000-0002-9313-9356
Serfling, Sebastian E.
Michalski, Kerstin
Lindner, Thomas
Schirbel, Andreas
Higuchi, Takahiro
Hartrampf, Philipp E.
Derlin, Thorsten
Buck, Andreas K.
Weich, Alexander
Werner, Rudolf A.
Funding for this research was provided by:
Japan Society for the Promotion of Science (21K19450)
Deutsche Forschungsgemeinschaft (453989101, 453989101, 507803309)
Universitätsklinikum Würzburg
Article History
Received: 25 January 2023
Accepted: 21 April 2023
First Online: 6 May 2023
Declarations
:
: This study was conducted according to the guidelines of the Declaration of Helsinki. The need for further ethical review and approval were waived by the local Ethics Committee due to the retrospective character of the study (waiver no. 20210415 02).
: Procedures were performed as part of clinical care. Informed consent was obtained from all subjects.
: TL is a co-inventor of a patent application for quinolone-based FAP-targeting agents for imaging and therapy in nuclear medicine. TL also has shares of a consultancy group for iTheranostics. All other authors declare no conflict of interest.